What is it about?

We realized a Delphi consensus on the role of first-line bevacizumab for HER2-negative metastatic breast cancer, involving a selected board of experts and a large community of oncologist.

Featured Image

Read the Original

This page is a summary of: A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer, Future Oncology, November 2016, Future Medicine,
DOI: 10.2217/fon-2016-0295.
You can read the full text:

Read

Contributors

The following have contributed to this page